| HER2阴性转移性乳腺癌病人二线治疗的有效性和安全性评估：RIBBON-2 |
| |
| 引用本文： | 王晓稼,钱学珂. HER2阴性转移性乳腺癌病人二线治疗的有效性和安全性评估：RIBBON-2[J]. 循证医学, 2012, 12(3): 153-156. DOI: 10.3969/j.issn.1671-5144.2012.03.017 |
| |
| 作者姓名： | 王晓稼 钱学珂 |
| |
| 作者单位： | 1. 浙江省肿瘤医院乳腺外科,杭州 310022; 2. 汕头大学医学院, 广东 汕头515031; 3. 广东省人民医院肿瘤中心、广东省医学科学院, 广州 510080 |
| |
| 摘 要： | 3背景 ·转移性乳腺癌（metastatic breast cancer,MBC）病人的一线治疗中,此前的3个Ⅲ期临床试验（E2100、AVADO和RIBBON-1）已经证实,贝伐单抗联合多种化疗药物,都可以提高患者的无进展生存率（progression-free survival,PFS）。
|
| 关 键 词： | 乳腺肿瘤 临床试验 Ⅲ期 贝伐单抗 转移 性乳腺癌 人表皮生长因子受体-2 |
RIBBON-2:Evaluating the Efficacy and Safety of Bevacizumab in Combination with Chemotherapy for Second-Line Treatment of Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer |
| |
| WANG Xiao-jia , QIAN Xue-ke. RIBBON-2:Evaluating the Efficacy and Safety of Bevacizumab in Combination with Chemotherapy for Second-Line Treatment of Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer[J]. The Journal of Evidence-Based Medicine, 2012, 12(3): 153-156. DOI: 10.3969/j.issn.1671-5144.2012.03.017 |
| |
| Authors: | WANG Xiao-jia QIAN Xue-ke |
| |
| Affiliation: | Reviewer’s address： Department of Breast Surgery, Zhejiang Cancer Hospital, Hangzhou 310022, China |
| |
| Abstract: | breast neoplasms clinical trial, phase Ⅲ Bevacizumab metastatic breast cancer human epidermalgrowth receptor-2 |
| |
| Keywords: | breast neoplasms clinical trial, phase Ⅲ Bevacizumab metastatic breast cancer human epidermalgrowth receptor-2 |
| 本文献已被 CNKI 维普 万方数据 等数据库收录！ |
| 点击此处可从《循证医学》浏览原始摘要信息 |
|
点击此处可从《循证医学》下载免费的PDF全文 |
